FY2026 Earnings Estimate for TRVI Issued By HC Wainwright

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) – Research analysts at HC Wainwright decreased their FY2026 earnings per share estimates for shares of Trevi Therapeutics in a research report issued on Tuesday, November 10th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.49) per share for the year, down from their previous estimate of ($0.48). HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at ($0.72) EPS.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13).

Other analysts have also issued reports about the company. Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 price objective on shares of Trevi Therapeutics in a research report on Friday, August 7th. BMO Capital Markets reissued an “outperform” rating on shares of Trevi Therapeutics in a report on Wednesday, October 7th. JonesTrading upped their target price on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Morgan Stanley reaffirmed an “overweight” rating and issued a $23.00 target price on shares of Trevi Therapeutics in a research note on Friday, August 7th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Trevi Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $27.08.

Read Our Latest Report on TRVI

Trevi Therapeutics Stock Performance

TRVI stock opened at $13.65 on Thursday. Trevi Therapeutics has a twelve month low of $9.82 and a twelve month high of $20.22. The business has a fifty day moving average of $14.03 and a 200-day moving average of $14.49.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. increased its position in shares of Trevi Therapeutics by 0.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 100,696 shares of the company’s stock valued at $1,442,000 after buying an additional 925 shares in the last quarter. AlphaCentric Advisors LLC lifted its holdings in Trevi Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 25,370 shares of the company’s stock worth $363,000 after acquiring an additional 1,053 shares in the last quarter. KBC Group NV bought a new position in Trevi Therapeutics during the first quarter worth about $29,000. Arizona State Retirement System grew its stake in Trevi Therapeutics by 12.9% in the second quarter. Arizona State Retirement System now owns 26,434 shares of the company’s stock valued at $493,000 after acquiring an additional 3,019 shares during the period. Finally, Sterling Capital Management LLC grew its stake in Trevi Therapeutics by 848.7% in the third quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock valued at $51,000 after acquiring an additional 3,191 shares during the period. Institutional investors own 95.76% of the company’s stock.

Insider Buying and Selling at Trevi Therapeutics

In other news, Director Michael Heffernan sold 39,473 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total value of $595,647.57. Following the transaction, the director directly owned 6,351 shares in the company, valued at $95,836.59. This trade represents a 86.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.39% of the stock is currently owned by company insiders.

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.

Featured Articles

Earnings History and Estimates for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.